aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Richard G. Gray, Daniel Rea, Kelly Handley, Sarah Jane Bowden, Philip Perry, Helena Margaret Earl, Christopher John Poole, Tom Bates, Shan Chetiyawardana, John A. Dewar, Indrajit Nalinika Fernando, Robert Grieve, Jonathan Nicoll, Zenor Rayter, Anne Robinson, Asad Salman, John Yarnold, Sarah Bathers, Andrea Marshall, Martin Lee, on behalf of the aTTom Collaborative Group
Institutions: University of Oxford, University of Birmingham, AO Foundation, NIHR Cambridge Biomedical Research Centre, University Hospital Coventry, University of Warwick, William Harvey Hospital, University Hospitals Birmingham NHS Foundation Trust, University of Dundee, Bristol NHS Foundation Trust, Southend University Hospital NHS Foundation Trust, Southend Hospital, Worthing Hospital, University Hospitals Sussex NHS Foundation Trust, Royal Marsden NHS Foundation Trust
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: tamoxifen, adjuvant endocrine therapy, estrogen receptor-positive breast cancer, early breast cancer, long-term treatment duration, breast cancer recurrence, breast cancer mortality, all-cause mortality, endometrial cancer, treatment discontinuation, medication adherence, hospitalization, quality of life, patient-reported outcomes, breast-conserving surgery
Open Access status: closed
OpenAlex ID: W1864994387
